Cerebrospinal fluid amino acids in pathological gamblers and healthy controls

Neuropsychobiology

Volumn 56, Issue 2-3, 2008, Pages 152-158

  Nordin, Conny ^a   Gupta, Ramesh C ^a,b   Sjödin, Ingemar ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NAGALAND UNIVERSITY   (India)

Author keywords

Amino acids; Cerebrospinal fluid; Pathological gambling

Indexed keywords

ASPARTIC ACID; CITRULLINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; GLUTAMINE; GLYCINE; ISOLEUCINE; LEUCINE; LYSINE; ORNITHINE; PHENYLALANINE;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; AMINO ACIDS; ANALYSIS OF VARIANCE; COMPULSIVE PERSONALITY DISORDER; FEMALE; GAMBLING; HUMANS; MALE; STATISTICS, NONPARAMETRIC;

EID: 40349098936     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000115782     Document Type: Article

References (27)

1. Blanco C, Ibánez A, Sáiz Ruiz J, Blanco-Jerez C, Nunes EV: Epidemiology, pathophysiology and treatment of pathological gambling. CNS Drugs 2000;13:397-407.
2. Raylu N, Oei TPS: Pathological gambling. A comprehensive review. Clin Psychol Rev 2002;22:1009-1061.
3. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE: Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviours. J Psychoactive Drugs 2000;32(suppl i-iv):1-112.
4. Roy A, Adinoff B, Roehrich L, Lamparski D, Custer R, Lorenz V, Barbaccia M, Guidotti A, Costa E, Linnoila M: Pathological gambling. A psychobiological study. Arch Gen Psychiatry 1988;45:369-373.
5. Bergh C, Eklund T, Södersten P, Nordin C: Altered dopamine function in pathological gambling. Psychol Med 1997;27:473-475.
6. Nordin C, Sjödin I: CSF monoamine patterns in pathological gamblers and healthy controls. J Psychiatr Res 2006;40:454-459.
7. Nordin C, Sjödin I: CSF cholecystokinin, γ-aminobutyric acid and neuropeptide Y in pathological gamblers and healthy controls. J Neural Transm 2007;114:499-503.
8. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 1985;147:276-282.
9. Coyle JT: Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res 2006;10:221-233.
10. Nordin C, Sjödin I: Altered CSF taurine function in pathological gambling. J Psychiatr Res 2006;40:473-474.
11. Gijsman HJ, Scarna A, Harmer CJ, McTavish SFB, Odontiadis J, Cowen PJ, Goodwin GM: A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. Psychopharmacology 2002;160:192-197.
12. Sevy S, Hassoun Y, Bechara A, Yechiam E, Napolitano B, Burdick K, Delman H, Malhotra A: Emotion based decision-making in healthy subjects: short-term effects of reducing dopamine levels. Psychopharmacology (Berl) 2006;1888:228-235.
13. Sur C, Kinney GG: Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. Curr Drug Targets 2007;8:643-649.
14. Nelson DL, Cox MM: Lehninger Principles of Biochemistry, ed 4. New York, WH Freeman and Company, 2005.
15. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
16. First MB, Gibbon M, Spitzer RL, Williams JBW: Structured Clinical Interview for DSMIV Axis I Disorders (SCID-I). Washington, American Psychiatric Press, 1997.
17. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS: Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, American Psychiatric Press, 1997.
18. Cloninger RC, Przybeck TR, Svrakic DM, Wetzel RD: The Temperament and Character Inventory (TCI): A Guide for Its Development and Use. St. Louis, Center for Psychobiology of Personality, 1994.
19. Nordin C, Nylander PO: Temperament and character in pathological gambling. J Gambl Stud 2007;23:113-120.
20. Eklundh T: Lumbar Puncture in Psychiatric Research - on the Impact of Confounding Factors on Monoamine Compounds in Cerebrospinal Fluid. Thesis, Stockholm, Karolinska Institute, 2000.
21. Qureshi GA, Baig S: Quantification of free amino acids in biological samples by high-performance liquid chromatography. J Chromatograph 1988;459:237-244.
22. Hill T, Lewicki P: Statistics. Methods and Applications. A Comprehensive Reference for Science, Industry, and Data Mining. Tulsa, StatSoft, 2006.
23. Coyle JT, Leski ML, Morrison JH: The diverse roles of L-glutamic acid in brain signal transduction; in Davis KL, Charney D, Coyle JT, Nemeroff C (eds): Neuropsychopharmacology. The Fifth Generation of Progress. Philadelphia, Lippincott Williams and Wilkins, 2002, p 74.
24. Grant JE, Kim SW, Odlaug BL: N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling; a pilot study. Biol Psychiatry 2007;62:652-657.
25. Lapish CC, Seamans JK, Judson Chandler L: Glutamate-dopamine cotransmission and reward processing in addiction. Alcohol Clin Exp Res 2006;30:1451-1465.
26. Mexal S, Frank M, Berger R, Adams CE, Ross RG, Freedman R, Leonard S: Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Brain Res Mol Brain Res 2005;139:317-332.
27. Whitehead KJ, Pearce SM, Walker G, Sundaram H, Hill D, Bowery NG: Positive N-methyl-D-aspartate receptor modulation by selective glycine transporter-1 inhibition in the rat dorsal spinal cord in vivo. Neuroscience 2004;126:381-390.